Explore All 41 PIPE Life Science Deals - Search the Database Free
Investment Summary |
|
|---|---|
| Date | October 25, 2010 |
| Target | Omeros |
| Sector | Life Science |
| Investor(s) |
Vulcan Capital
CRG Athyrium Capital Management |
| Deal Type | PIPE |
FILTER BY
| Category | Family Office |
|---|---|
| Founded | 1986 |
| Size | Mega |
| Type | Sector Agnostic |
Vulcan Capital is the private investment group of Vulcan Inc., the organization founded by Paul G. Allen to manage his personal and professional endeavors. Vulcan Capital looks to invest at all company stages and will consider opportunities across an array of industries. Sectors of interest include business services, consumer products, distribution and logistics, energy and natural resources, financial services and insurance, healthcare, manufacturing, media, technology, and telecom. The Firm's target investment size is $10 to $100 million. In addition to direct investing, Vulcan Capital also makes fund investments as well as invests in public securities. Vulcan Inc. was formed in 1986 and has offices in Seattle, Washington and Palo Alto, California.
| Deal Context for Investor | # |
|---|---|
| Overall | 19 of 35 |
| Sector: Life Science | 4 of 5 |
| Type: PIPE | 1 of 1 |
| State: Washington | 2 of 2 |
| Country: United States | 18 of 30 |
| Year: 2010 | 2 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2010-10-20 |
SiOnyx
Beverly, Massachusetts, United States SiOnyx is commercializing a patented semiconductor process that dramatically enhances the infrared sensitivity of silicon-based photonics. As a result, SiOnyx’s Black Silicon platform represents a significant breakthrough in the development of smaller, lower cost, higher performance photonic devices. SiOnyx was founded in 2006 and is based in Beverly, Massachusetts. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2011-02-14 |
Gist
Seattle, Washington, United States Gist is an online service that integrates the social stream with tools like Microsoft Outlook and Salesforce.com. Gist removes the noise from individual email alerts, eliminates the hassle of going to multiple services to get news and updates about contacts, and automates the delivery and presentation of the most important information about the contacts in a user’s professional network. By spanning the most on-line contact and content sources, Gist users are better informed with insights and actionable information about clients, prospects, and contacts. |
Sell | - |
CRG is a healthcare focused investment firm focused on growth capital to commercial-stage public and private companies. CRG looks to commit $20 to $300 million that are developing next-generation healthcare products, technologies and services that address significant and substantial unmet medical needs. Specific areas of interest include biopharmaceuticals, specialty pharmaceuticals, medical devices, drug delivery, animal health, tools and diagnostics, and healthcare services. CRG was formed in 2003 and is headquartered in Houston, Texas.
| Deal Context for Investor | # |
|---|---|
| Overall | 1 of 13 |
| Sector: Life Science | 1 of 1 |
| Type: PIPE | 1 of 1 |
| State: Washington | 1 of 1 |
| Country: United States | 1 of 12 |
| Year: 2010 | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2011-11-29 |
Hicuity Health
St. Louis, Missouri, United States Hicuity Health is a provider of high acuity telehealth services, serving approximately 100 hospitals in 26 states on a 24 x 7 x 365 basis. Hicuity Health was founded in 2005 and is based in St. Louis, Missouri. |
Buy | - |
| Category | Asset Manager |
|---|---|
| Founded | 2008 |
| PE ASSETS | 4.6B USD |
| Size | Large |
| Type | Sector Focused |
Athyrium Capital Management is a large asset manager focused on the healthcare sector. Athyrium invests in a wide range of financial instruments including royalties, structured credit, and equities as well as select special situations. Athyrium Capital was established in 2008 and is headquartered in New York, New York.
| Deal Context for Investor | # |
|---|---|
| Overall | 1 of 50 |
| Sector: Life Science | 1 of 24 |
| Type: PIPE | 1 of 3 |
| State: Washington | 1 of 1 |
| Country: United States | 1 of 45 |
| Year: 2010 | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2011-01-01 |
Alcresta Therapeutics
Waltham, Massachusetts, United States Alcresta Therapeutics is a biotechnology company that develops and commercializes enzyme‑based products to address fat malabsorption in people with gastrointestinal disorders and rare diseases. It uses a proprietary technology platform to create solutions that help break down fats in enteral nutrition, supporting patients who have difficulty absorbing nutrients. The company’s work is centered on improving nutritional care for patients who rely on tube feeding. Alcresta Therapeutics was formed in 2011 and is based in Waltham, Massachusetts. |
Buy | - |
